跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 4,909 条关于
“CCM-245”
全部
4,909
临床试验
3,398
药物
958
机构
43
资讯
510
去年
CCM Biosciences to Present Breakthrough 4th-Generation EGFR Inhibitors for NSCLC at ASCO 2025
去年
Recursion's REC-994 Shows Promising Safety and Efficacy Signals in Phase 2 CCM Trial
去年
Recursion's REC-994 Shows Promise in Phase II Trial for Cerebral Cavernous Malformations
2年前
Recursion's AI-Derived Drug REC-994 Shows Promise in Phase 2 Trial for Cerebral Cavernous Malformation
去年
Recursion's AI-Discovered Drug Shows Promise in Phase II Brain Disease Trial
去年
UVA Health Develops Breakthrough Non-Invasive Ultrasound Treatment for Cerebral Cavernous Malformations
2年前
AI-Driven Drug Discovery Shows Promise and Challenges in Cerebral Cavernous Malformation Trial
3年前
Johnson & Johnson Expands Cell Therapy Portfolio with Cellular Biomedicine Group Deal
2年前
Recursion Anticipates Phase 2 Data Readouts and Advances Platform Capabilities
去年
Real-World Data Confirms High Effectiveness of RSV Vaccines in Older Adults
第 1 页,共 51 页
上一页
下一页